These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

871 related articles for article (PubMed ID: 23679050)

  • 1. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
    Kingsberg SA; Wysocki S; Magnus L; Krychman ML
    J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate.
    Krychman M; Graham S; Bernick B; Mirkin S; Kingsberg SA
    J Sex Med; 2017 Mar; 14(3):425-433. PubMed ID: 28202319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.
    Nappi RE; Palacios S; Panay N; Particco M; Krychman ML
    Climacteric; 2016 Apr; 19(2):188-97. PubMed ID: 26581580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Women's EMPOWER Survey: Identifying Women's Perceptions on Vulvar and Vaginal Atrophy and Its Treatment.
    Kingsberg SA; Krychman M; Graham S; Bernick B; Mirkin S
    J Sex Med; 2017 Mar; 14(3):413-424. PubMed ID: 28202320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey in Europe: Country-specific comparisons of postmenopausal women's perceptions, experiences and needs.
    Nappi RE; Palacios S; Particco M; Panay N
    Maturitas; 2016 Sep; 91():81-90. PubMed ID: 27451325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attitudes and perceptions towards vulvar and vaginal atrophy in Italian post-menopausal women: Evidence from the European REVIVE survey.
    Nappi RE; Particco M; Biglia N; Cagnacci A; Di Carlo C; Luisi S; Paoletti AM
    Maturitas; 2016 Sep; 91():74-80. PubMed ID: 27451324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe.
    DiBonaventura M; Luo X; Moffatt M; Bushmakin AG; Kumar M; Bobula J
    J Womens Health (Larchmt); 2015 Sep; 24(9):713-22. PubMed ID: 26199981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceptions of dyspareunia in postmenopausal women with vulvar and vaginal atrophy: findings from the REVIVE survey.
    Freedman MA
    Womens Health (Lond); 2014 Jul; 10(4):445-54. PubMed ID: 25259904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions.
    Palacios S; Cancelo MJ; Castelo Branco C; Llaneza P; Molero F; Borrego RS
    Climacteric; 2017 Feb; 20(1):55-61. PubMed ID: 28042734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estradiol softgel inserts for the treatment of VVA symptoms: an expert opinion.
    Liu JH; Bernick B; Mirkin S
    Expert Opin Drug Deliv; 2020 Nov; 17(11):1573-1581. PubMed ID: 32877254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macro-regional variation in attitudes toward and experiences of vulvar and vaginal atrophy among Italian post-menopausal women: a post hoc analysis of REVIVE survey data.
    Nappi RE; Particco M; Biglia N; Cagnacci A; Di Carlo C; Luisi S; Paoletti AM
    Gynecol Endocrinol; 2017 May; 33(5):389-394. PubMed ID: 28277131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
    De Seta F; Caruso S; Di Lorenzo G; Romano F; Mirandola M; Nappi RE
    Maturitas; 2021 May; 147():34-40. PubMed ID: 33832645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptoms, attitudes and treatment perceptions of vulvo-vaginal atrophy in UK postmenopausal women: Results from the REVIVE-EU study.
    Domoney C; Short H; Particco M; Panay N
    Post Reprod Health; 2020 Jun; 26(2):101-109. PubMed ID: 32627698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and impact of vaginal symptoms among postmenopausal women.
    Santoro N; Komi J
    J Sex Med; 2009 Aug; 6(8):2133-42. PubMed ID: 19493278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The American-European difference in vulvar and vaginal atrophy views: a lesson from the REVIVE Survey.
    Nappi RE; Krychman ML
    Climacteric; 2016 Jun; 19(3):252-5. PubMed ID: 27094975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women.
    Panay N; Palacios S; Bruyniks N; Particco M; Nappi RE;
    Maturitas; 2019 Jun; 124():55-61. PubMed ID: 31097180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of vulvovaginal atrophy on women's quality of life from an Italian cohort of the EVES study.
    Nappi RE; Di Carlo C; Becorpi AM; Gambacciani M; De Seta F; Ribaldone R; Benedetto C; Paoletti AM;
    J Obstet Gynaecol; 2020 May; 40(4):512-519. PubMed ID: 31496326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device.
    Vicariotto F; Raichi M
    Minerva Ginecol; 2016 Jun; 68(3):225-36. PubMed ID: 27206062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.
    Simon JA; Kagan R; Archer DF; Constantine GD; Bernick B; Graham S; Mirkin S
    Climacteric; 2019 Aug; 22(4):412-418. PubMed ID: 30862193
    [No Abstract]   [Full Text] [Related]  

  • 20. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
    J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.